ReviewMicroorganisms2017
Approaches to Dispersing Medical Biofilms.
Review in Microorganisms, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Antibacterial and antibiofilm activities of pyocins produced byFrontiers in microbiology · 2026Pooled it
- Understanding bacterial biofilms: From definition to treatment strategies.Frontiers in cellular and infection microbiology · 2023Pooled it
- Integrated Approach for the Discovery of Antifungal and Antibiofilm Agents From Cerrado Plants.Chemistry & biodiversity · 2026Article
- Agent-based modeling of erosion and sloughing during growth of Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2026Article
- n-Butanol Extract ofCurrent issues in molecular biology · 2026Article
- Nanostructured Hydrogels: A Method to Prevent Biofilms on Implantable Medical Devices.Gels (Basel, Switzerland) · 2026Review
- Rapid means of biofilm disruption induce the newly released (NRel) phenotype of enhanced antibiotic sensitivity.Frontiers in microbiology · 2026Article
- Dental devices and antimicrobial resistance: challenges, innovations, and regulatory compliances.Frontiers in medical technology · 2026Review
- Emerging Multimodal Strategies for Bacterial Biofilm Eradication: A Comprehensive Review.Microorganisms · 2025Review
- Quinazoline-Derivatives of Imino-1,2,3-Dithiazoles Promote Biofilm Dispersion ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Biosurfactants as novel antibiofilm agents: mechanisms, biomedical applications, and applications in biofilm-associated infections.Archives of microbiology · 2025Review
- α-Amylase-Mediated Antibiotic Degradation and Sequestration inAntibiotics (Basel, Switzerland) · 2025Article
- Targeting Bacterial Biofilms on Medical Implants: Current and Emerging Approaches.Antibiotics (Basel, Switzerland) · 2025Review
- Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.Microbial biotechnology · 2025Review
- Squalamine and claramine A1 disperseBiofilm · 2025Article
- TargetingBiofilm · 2025Article
- Gut Mycobiome: Latest Findings and Current Knowledge Regarding Its Significance in Human Health and Disease.Journal of fungi (Basel, Switzerland) · 2025Review
- Biofilm Dispersal inMicroorganisms · 2025Article
- Article
- Biofilm Dispersal and Wound Infection Clearance With Preclinical Debridement Agents.International wound journal · 2025Article
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Biofilm-associated infections pose a complex problem to the medical community, in that residence within the protection of a biofilm affords pathogens greatly increased tolerances to antibiotics and antimicrobials, as well as protection from the host immune response. This results in highly recalcitrant, chronic infections and high rates of morbidity and mortality. Since as much as 80% of human bacterial infections are biofilm-associated, many researchers have begun investigating therapies that specifically target the biofilm architecture, thereby dispersing the microbial cells into their more vulnerable, planktonic mode of life. This review addresses the current state of research into medical biofilm dispersal. We focus on three major classes of dispersal agents: enzymes (including proteases, deoxyribonucleases, and glycoside hydrolases), antibiofilm peptides, and dispersal molecules (including dispersal signals, anti-matrix molecules, and sequestration molecules). Throughout our discussion, we provide detailed lists and summaries of some of the most prominent and extensively researched dispersal agents that have shown promise against the biofilms of clinically relevant pathogens, and we catalog which specific microorganisms they have been shown to be effective against. Lastly, we discuss some of the main hurdles to development of biofilm dispersal agents, and contemplate what needs to be done to overcome them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.